This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hurley, K. E. Articles by Chapman, P. B. Search for Related Content PubMed PubMed Citation Articles by Hurley, K. E. Articles by Chapman, P. B.

Helping Melanoma Patients Decide Whether to Choose Adjuvant High-Dose Interferon-2b

Department of Psychiatry and Behavioral Sciences, and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA

Key Words. Adjuvant treatment • Interferon • Melanoma • Risk–benefit • Survival

Correspondence: Paul B. Chapman, M.D., Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA. Telephone: 212-639-5015; Fax: 212-704-4352; e-mail: chapmanp{at}mskcc.org

High-dose interferon-2b is a U.S. Food and Drug Administration–approved adjuvant treatment for stage III melanoma, and yet, because of its limited efficacy and well-known toxicity, it is not universally accepted by patients and oncologists. In this paper, we evaluate the benefits and risks of adjuvant high-dose interferon-2b and try to provide a framework to help oncologists guide patients trying to decide whether to undergo adjuvant high-dose interferon therapy.

This article has been cited by other articles:

				A. A. Tarhini, J. Shipe-Spotloe, M. DeMark, S. S. Agarwala, and J. M. Kirkwood Response to "Helping Melanoma Patients Decide Whether to Choose Adjuvant High-Dose Interferon-{alpha}2b". Oncologist, May 1, 2006; 11(5): 538 - 539. [Full Text] [PDF]